Retatrutide: The Triple-Receptor Trials
Retatrutide, development code LY3437943, is a 39-amino-acid peptide, formula C221H342N46O68, with agonist activity at three receptors: GIP, GLP-1, and glucagon. That third receptor is what distinguishes it from dual agonists like tirzepatide.
Two phase 2 trials were published in 2023. A phase 2 obesity trial by Jastreboff and colleagues in the New England Journal of Medicine examined weight-related endpoints across a dose range, reporting mean weight reduction up to 17.5% at 24 weeks and 24.2% at 48 weeks in the highest-dose group. A phase 2 type 2 diabetes trial by Rosenstock and colleagues in the Lancet examined glycaemic and body-weight endpoints against placebo and dulaglutide as an active comparator.
Both are human trials in high-impact journals. Retatrutide is investigational and holds no marketing approval.
Supplied for laboratory research use only.
References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi.org/10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi.org/10.1016/S0140-6736(23)01053-X
